- Home
- OPRX vs SLN Comparison
OPRX vs SLN Comparison
Compare OPRX & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPRX
- SLN
- Stock Information
- Founded
- OPRX 2006
- SLN 1994
- Country
- OPRX United States
- SLN United Kingdom
- Employees
- OPRX N/A
- SLN N/A
- Industry
- OPRX Business Services
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- OPRX Consumer Discretionary
- SLN Health Care
- Exchange
- OPRX Nasdaq
- SLN Nasdaq
- Market Cap
- OPRX 234.9M
- SLN 268.8M
- IPO Year
- OPRX N/A
- SLN N/A
- Fundamental
- Price
- OPRX $17.78
- SLN $5.01
- Analyst Decision
- OPRX Buy
- SLN Buy
- Analyst Count
- OPRX 8
- SLN 6
- Target Price
- OPRX $11.81
- SLN $39.67
- AVG Volume (30 Days)
- OPRX 366.6K
- SLN 51.7K
- Earning Date
- OPRX 11-12-2025
- SLN 11-13-2025
- Dividend Yield
- OPRX N/A
- SLN N/A
- EPS Growth
- OPRX N/A
- SLN N/A
- EPS
- OPRX N/A
- SLN N/A
- Revenue
- OPRX $104,748,000.00
- SLN $27,169,000.00
- Revenue This Year
- OPRX $17.92
- SLN N/A
- Revenue Next Year
- OPRX $10.91
- SLN N/A
- P/E Ratio
- OPRX N/A
- SLN N/A
- Revenue Growth
- OPRX 25.89
- SLN 22.28
- 52 Week Low
- OPRX $3.78
- SLN $1.97
- 52 Week High
- OPRX $19.25
- SLN $20.48
- Technical
- Relative Strength Index (RSI)
- OPRX 54.44
- SLN 46.85
- Support Level
- OPRX $17.07
- SLN $4.42
- Resistance Level
- OPRX $18.85
- SLN $5.80
- Average True Range (ATR)
- OPRX 1.10
- SLN 0.37
- MACD
- OPRX -0.16
- SLN -0.01
- Stochastic Oscillator
- OPRX 42.35
- SLN 42.75
About OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.